Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:FNCH NASDAQ:HOTH NASDAQ:INM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.70+0.2%$2.49$1.55▼$4.49$19.28M0.07135,867 shs12,373 shsFNCHFinch Therapeutics Group$12.05$12.39$10.15▼$15.85$19.35M1.172,274 shs68 shsHOTHHoth Therapeutics$1.37+0.7%$1.51$0.66▼$3.80$18.16M0.671.06 million shs325,607 shsINMInMed Pharmaceuticals$2.07+2.0%$2.21$1.72▼$8.27$4.94M0.3116,064 shs50,543 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech0.00%+14.19%+10.45%+12.76%-26.77%FNCHFinch Therapeutics Group0.00%-0.41%-4.21%-3.98%+0.42%HOTHHoth Therapeutics0.00%-2.14%-24.31%+7.03%+63.02%INMInMed Pharmaceuticals0.00%-1.43%-5.05%-21.59%-65.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.70+0.2%$2.49$1.55▼$4.49$19.28M0.07135,867 shs12,373 shsFNCHFinch Therapeutics Group$12.05$12.39$10.15▼$15.85$19.35M1.172,274 shs68 shsHOTHHoth Therapeutics$1.37+0.7%$1.51$0.66▼$3.80$18.16M0.671.06 million shs325,607 shsINMInMed Pharmaceuticals$2.07+2.0%$2.21$1.72▼$8.27$4.94M0.3116,064 shs50,543 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech0.00%+14.19%+10.45%+12.76%-26.77%FNCHFinch Therapeutics Group0.00%-0.41%-4.21%-3.98%+0.42%HOTHHoth Therapeutics0.00%-2.14%-24.31%+7.03%+63.02%INMInMed Pharmaceuticals0.00%-1.43%-5.05%-21.59%-65.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 2.50Moderate Buy$5.0085.53% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AHOTHHoth Therapeutics 2.33Hold$4.50228.47% UpsideINMInMed Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest INM, FNCH, HOTH, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025HOTHHoth TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025EDSAEdesa BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025EDSAEdesa BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025HOTHHoth TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025EDSAEdesa BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025HOTHHoth TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/18/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/30/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AINMInMed Pharmaceuticals$4.94M1.00N/AN/A$6.71 per share0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.32N/AN/AN/AN/A-162.95%-60.33%12/12/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AHOTHHoth Therapeutics-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)INMInMed Pharmaceuticals-$8.16M-$12.09N/A∞N/A-165.12%-93.19%-74.49%11/13/2025 (Estimated)Latest INM, FNCH, HOTH, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025HOTHHoth Therapeutics-$0.27-$0.17+$0.10-$0.17N/AN/A8/8/2025Q3 2025EDSAEdesa Biotech-$0.26-$0.25+$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A18.9618.96FNCHFinch Therapeutics GroupN/A3.873.87HOTHHoth TherapeuticsN/A27.5427.54INMInMed Pharmaceuticals0.026.996.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%FNCHFinch Therapeutics Group21.77%HOTHHoth Therapeutics7.08%INMInMed Pharmaceuticals20.12%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%FNCHFinch Therapeutics Group44.90%HOTHHoth Therapeutics6.92%INMInMed Pharmaceuticals1.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.04 million5.45 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataHOTHHoth Therapeutics413.26 million12.34 millionNot OptionableINMInMed Pharmaceuticals102.38 million2.35 millionNot OptionableINM, FNCH, HOTH, and EDSA HeadlinesRecent News About These CompaniesInmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of DirectorsOctober 16, 2025 | newsfilecorp.comNInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNInMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last yearSeptember 23, 2025 | msn.comInMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 23, 2025 | newsfilecorp.comNInMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025September 16, 2025 | financialpost.comFInMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025September 16, 2025 | globenewswire.comCannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightAugust 13, 2025 | finance.yahoo.comInMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025July 28, 2025 | newsfilecorp.comNInMed Pharmaceuticals Secures $5M in Private PlacementJuly 3, 2025 | theglobeandmail.comInMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq RulesJune 27, 2025 | newsfilecorp.comNInMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 25, 2025 | newsfilecorp.comNInMed stock soars after promising Alzheimer’s drug preclinical resultsJune 24, 2025 | in.investing.comInMed Shares Jump After Positive Preclinical Data for INM-901June 24, 2025 | marketwatch.comInMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo StudyJune 24, 2025 | newsfilecorp.comNInMed Pharmaceuticals: InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes ...June 14, 2025 | finanznachrichten.deInMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPAJune 13, 2025 | newsfilecorp.comNNew CB1 and CB2 receptor modulators disclosed in Inmed patentMay 31, 2025 | bioworld.comBInMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 12, 2025 | newsfilecorp.comNInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Robinhood Up 12%—Could Prediction Markets Be Its Secret Weapon?By Leo Miller | October 3, 20253 Travel Stocks to Watch Heading Into the HolidaysBy Chris Markoch | October 6, 2025INM, FNCH, HOTH, and EDSA Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.70 +0.01 (+0.19%) Closing price 10/24/2025 03:52 PM EasternExtended Trading$2.70 +0.01 (+0.22%) As of 10/24/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Finch Therapeutics Group NASDAQ:FNCH$12.05 0.00 (0.00%) As of 10/24/2025Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Hoth Therapeutics NASDAQ:HOTH$1.37 +0.01 (+0.74%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.37 0.00 (0.00%) As of 10/24/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.InMed Pharmaceuticals NASDAQ:INM$2.07 +0.04 (+1.97%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.08 +0.02 (+0.72%) As of 10/24/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
